Home›Companies›Healthcare›Acclinate

Acclinate, Inc.

Acclinate helps clinical research teams recruit participants through community outreach and predictive software.

Updated Nov 10, 2026·Latest SEC filing Apr 14, 2026·Suggest an edit

About Acclinate

Acclinate is a private company based in Birmingham, Alabama. It has reported $14,436,386 raised in three offerings on Form D since October 2022. Its chief executive is Delmonize Smith.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Feb 11, 2026Apr 14, 2026$3,500,000fully sold5$700KDebt, Options, Securities on exerciseRule 506(b)Form D ↗
May 3, 2024May 17, 2024$5,999,977of $7.0M target6$999KEquityRule 506(b)Form D ↗
Oct 3, 2022Oct 19, 2022$4,936,409fully sold25$197KEquityRule 506(b)Form D ↗
Total, three offerings$14,436,386

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Acclinate's Form D filed Apr 14, 2026.

JD
Jason Dinger
Director
DS
Delmonize Smith
Co-Founder & CEO, director
TW
Tiffany Whitlow
Co-Founder & Chief Development Officer, director

Earlier filings also listed Charles Cycon (director, last listed May 2024).

Sources

  1. SECAcclinate, Inc. filing history
  2. CompanyPrivacy policy
  3. CompanyAbout Acclinate